Zerviate (cetirizine ophthalmic) dosing, indications, interactions, adverse effects, and more

Sections

Sections cetirizine ophthalmic
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

0.24%

Allergic Conjunctivitis

Indicated for ocular itching associated with allergic conjunctivitis

Instill 1 drop in each affected eye BID (~8 hr apart)

Dosage Forms & Strengths

ophthalmic solution

0.24%

Allergic Conjunctivitis

Indicated for ocular itching associated with allergic conjunctivitis

<2 years: Safety and efficacy not established

≥2 years: Instill 1 drop in each affected eye BID (~8 hr apart)

1-10%

Hyperemia (1-7%)

Instillation site pain (1-7%)

Reduced visual acuity (1-7%)

Contraindications

None

Cautions

Care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container in order to avoid injury to the eye and to prevent contaminating the tip and solution; keep the bottle closed when not in use; discard the single- use container after using in each eye

Advise patient to not wear contact lenses if their eye is red

Do not instill drops while wearing contact lenses; remove contacts before instillation; may be reinserted 10 minutes after administration; benzalkonium chloride (preservative) may be absorbed by soft contact lenses

Not for treatment of contact lens-related irritation

Pregnancy

No adequate or well-controlled studies of cetirizine ophthalmic in pregnant women

Use in pregnancy only if potential benefit justifies potential risk to fetus

Lactation

Unknown if ophthalmic cetirizine distributed in human breast milk; orally administered cetirizine is excreted in human breast milk

Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Histamine-1 receptor antagonist; inhibits histamine release from mast cells, decreases chemotaxis, and inhibits eosinophil activation

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]